Cerecor Inc. (NASDAQ:CERC) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On March 20, 2019, Cerecor Inc. will be presenting at the Oppenheimer& Co. Inc. 29th Annual Healthcare Conference in New York. A copy of this slide show presentation made at the conference is attached hereto as Exhibit 99.1.
The information in this Item 7.01 (including Exhibit99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Cerecor Inc. Slide Show Presentation.
|
Cerecor Inc. Exhibit
EX-99.1 2 cerecorcorporatehighligh.htm EXHIBIT 99.1 cerecorcorporatehighligh Exhibit 99.1 Cerecor Corporate Highlights March | 2019 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Cerecor’s control),…
To view the full exhibit click here
About Cerecor Inc. (NASDAQ:CERC)
Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson’s disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.
